Miracle H

Product Overview

Miracle H is a South Korean PCL and hyaluronic acid (HA) skin booster developed by DEXLEVO Co., Ltd. Formulated with 20% solubilized polycaprolactone (PCL) and 1% hyaluronic acid, Miracle H combines a biodegradable collagen-stimulating polymer with a moisture-binding ingredient. It is supplied as a ready-to-use liquid formulation in 2 mL vials, with five vials per standard box.

Miracle H belongs to the DEXLEVO Miracle series of PCL-based aesthetic formulations. Its dual-component formulation is commercially positioned for professional skin rejuvenation applications involving hydration, elasticity, skin texture, and the appearance of fine lines.

Unlike conventional particulate PCL fillers, Miracle H is described by its developer as incorporating solubilized PCL technology. This formulation concept is intended to support the distribution of PCL within tissue while promoting collagen-related biological responses.

The addition of hyaluronic acid distinguishes Miracle H from Miracle L, the related PCL-based formulation within the same product family. Miracle H combines PCL with HA for hydration-oriented skin conditioning, while Miracle L is marketed primarily around its PCL component.

This TEOSQUARE product page provides professional buyers with information about Miracle H's composition, formulation technology, packaging specifications, ingredient characteristics, storage requirements, and regulatory considerations.

Key Features

• 20% Solubilized Polycaprolactone: Contains a manufacturer-reported 20% PCL component based on DEXLEVO's solubilized polymer formulation technology.
• 1% Hyaluronic Acid: Combines PCL with 1% HA, a hydrophilic ingredient recognized for its water-binding properties and role in tissue hydration.
• PCL-Based Collagen Stimulation: Uses a biodegradable synthetic polymer investigated for its ability to induce collagen-related tissue responses in selected aesthetic formulations.
• Solubilized PCL Technology: Developed using a formulation concept intended to distribute PCL without relying on the conventional large polymer microparticles found in certain collagen-stimulating fillers.
• Ready-to-Use Liquid Formulation: Supplied as a liquid solution rather than a freeze-dried powder requiring reconstitution.
• 2 mL Vial Presentation: Each vial contains 2 mL, with five vials per standard manufacturer-style package.
• South Korean Product Development: Developed by DEXLEVO, a South Korean company specializing in PCL-based aesthetic biomaterials.

Composition & Specifications

Miracle H combines polycaprolactone and hyaluronic acid as its two principal functional ingredients. Published product specifications identify 20% PCL and 1% HA.

The formulation also contains supporting components, including polyethylene glycol, glycerin, sodium carboxymethylcellulose, sodium lactate, and sodium pyroglutamic acid.

Polycaprolactone (PCL)

Polycaprolactone is a synthetic, biodegradable polyester used in various biomedical applications. Its chemical structure consists of repeating caprolactone units connected through ester bonds.

PCL has attracted interest in aesthetic medicine because certain PCL-based implants and injectable formulations can stimulate collagen-related tissue responses.

Research involving selected PCL dermal fillers has demonstrated the formation of new collagen around implanted polymer materials. This biological response is commonly described as neocollagenesis.

Miracle H uses a solubilized PCL formulation rather than the conventional particulate structure used in some established PCL fillers. The developer describes this technology as a means of improving polymer distribution within tissue.

The manufacturer-reported PCL content is 20%. However, the precise analytical basis for this percentage and the complete polymer specifications should be verified against current manufacturer-issued technical documentation.

Hyaluronic Acid (HA)

Hyaluronic acid is a naturally occurring glycosaminoglycan found in the extracellular matrix of connective tissues, including the skin.

Its hydrophilic molecular structure allows it to interact with water molecules, contributing to tissue hydration and viscoelasticity.

Miracle H contains 1% hyaluronic acid, commonly identified as sodium hyaluronate in published ingredient declarations.

This HA component distinguishes Miracle H from Miracle L and supports the product's commercial positioning as a hydration-oriented PCL skin booster.

The presence of HA does not independently establish immediate clinical skin improvement, a specific duration of hydration, or additional collagen synthesis.

Polyethylene Glycol (PEG)

Polyethylene glycol is a hydrophilic polymer used in pharmaceutical, medical, and cosmetic formulations.

Depending on its molecular characteristics and concentration, PEG may contribute to solubilization, formulation stability, and other physicochemical properties.

PEG is identified among the supporting ingredients of Miracle H, although its exact quantitative concentration has not been established from the available product specifications.

Glycerin

Glycerin is a water-soluble polyol commonly used as a humectant in cosmetic and pharmaceutical formulations.

It interacts with water and can contribute to the moisture-retaining characteristics of a formulation.

Its presence in Miracle H should be understood as part of the overall formulation rather than evidence of a specific clinical moisturizing effect.

Sodium Carboxymethylcellulose

Sodium carboxymethylcellulose is a water-soluble cellulose derivative commonly used to modify viscosity and support the physical characteristics of liquid formulations.

Depending on the formulation, it may function as a thickening or stabilizing agent.

Sodium Lactate and Sodium Pyroglutamic Acid

Sodium lactate and sodium pyroglutamic acid, also known as sodium PCA, are ingredients associated with moisture management and skin-conditioning formulations.

Both compounds are related to substances present in or associated with the skin's natural moisturizing environment.

Their inclusion does not independently establish clinically demonstrated improvements in skin barrier function or hydration following administration of Miracle H.

The 20% PCL and 1% HA specifications are consistently reported in Korean and international product information. The exact quantitative composition of supporting ingredients, polymer molecular characteristics, and concentration calculation methods require confirmation from manufacturer-issued technical documentation.

How Miracle H Is Formulated to Work

Miracle H combines two ingredients with different physicochemical and biological characteristics: biodegradable polycaprolactone and hydrophilic hyaluronic acid.

The formulation is commercially positioned to combine PCL-associated collagen stimulation with HA-associated moisture retention.

PCL and Collagen-Related Tissue Responses

Polycaprolactone-based biomaterials have been investigated for their ability to promote collagen formation following implantation in tissue.

In selected PCL filler formulations, interactions between implanted polymer materials and surrounding tissue can stimulate fibroblast activity and extracellular matrix remodeling.

Fibroblasts are connective tissue cells involved in producing collagen and other extracellular matrix components.

The formation of new collagen in response to certain implanted biomaterials is commonly referred to as neocollagenesis.

Although this mechanism provides a scientific basis for PCL-based aesthetic formulations, clinical findings from particulate PCL fillers cannot automatically be attributed to Miracle H's solubilized PCL formulation.

Solubilized PCL Formulation Technology

DEXLEVO describes its Miracle series as incorporating solubilized PCL technology developed for aesthetic applications.

The company's published technical materials describe a formulation approach designed to distribute PCL more uniformly than conventional polymer microparticle-based preparations.

This technology is associated with the developer's broader research into biodegradable polymer formulations.

However, the manufacturer's descriptions of polymer solubilization and tissue distribution should not be interpreted as proof that the finished product is free from nodules, inflammation, granulomas, or other complications.

Hyaluronic Acid and Hydration

Hyaluronic acid has a strong affinity for water and contributes to hydration within biological tissues.

Miracle H incorporates 1% HA to complement its PCL-based formulation.

The combination is positioned to support hydration-oriented skin conditioning alongside PCL-associated tissue responses.

The magnitude and duration of any clinical hydration effect depend on the finished formulation, tissue environment, and application conditions.

Biodegradation of Polycaprolactone

Polycaprolactone is biodegradable through processes involving the hydrolysis of ester bonds within its polymer structure.

Its degradation characteristics depend on molecular weight, polymer architecture, formulation, and the surrounding biological environment.

Commercial Miracle H descriptions frequently refer to aesthetic effects lasting approximately 6–12 months. However, a definitive duration of clinical effectiveness for the finished product cannot be established solely from general PCL biodegradation research.

The mechanisms described above are based on established properties of PCL and HA, together with the manufacturer's formulation concept. They do not establish product-specific clinical superiority, guaranteed collagen production, or a predictable duration of aesthetic improvement.

Miracle H Formulation Characteristics

Miracle H is commercially distinguished by combining solubilized PCL with hyaluronic acid in a ready-to-use liquid formulation.

Its dual-component composition differs from products formulated exclusively around HA hydration or particulate collagen-stimulating materials.

• PCL-Based Biostimulation Concept: Uses a biodegradable polymer associated with collagen-related tissue responses in aesthetic biomaterial research.
• HA-Enhanced Hydration Positioning: Contains 1% hyaluronic acid to complement the PCL component with water-binding properties.
• Liquid Formulation: Supplied as a prepared liquid rather than a powder requiring reconstitution.
• Solubilized Polymer Technology: Incorporates DEXLEVO's formulation concept designed around solubilized PCL rather than conventional large polymer microparticles.
• Professional Aesthetic Positioning: Marketed for skin-conditioning applications involving the appearance of fine lines, skin texture, hydration, and elasticity.

Miracle H is commonly discussed in professional aesthetic markets as a collagen-stimulating skin booster rather than a conventional cross-linked HA volumizing filler.

Its specific legal product classification and permitted applications must be established from the original product documentation and destination-country regulatory requirements.

The formulation's commercial positioning does not independently establish approved indications or clinical effectiveness for wrinkle reduction, scar correction, facial lifting, or other aesthetic outcomes.

Miracle H and the Miracle Product Series

The DEXLEVO Miracle series includes Miracle H and Miracle L, two related PCL-based formulations with different ingredient compositions.

Miracle H combines solubilized PCL with hyaluronic acid, while Miracle L is positioned as a PCL-based formulation without the additional HA component.

Miracle H should not be confused with Miracle L or other PCL products developed by DEXLEVO. Similar polymer technology does not establish identical composition, clinical performance, regulatory authorization, or safety characteristics.

This page describes Miracle H only. Product specifications belonging to Miracle L or other DEXLEVO formulations should not be assigned to Miracle H without independent verification.

Packaging & Product Presentation

Miracle H is supplied as a liquid formulation in individual 2 mL glass vials.

The standard manufacturer-style packaging contains five vials, providing a total nominal volume of 10 mL per box.

Some international distributors sell individual 2 mL vials separately from complete five-vial boxes.

Professional buyers should verify whether the selected TEOSQUARE product option refers to one vial or a complete box.

The original product label should also be checked for the complete product name, batch number, expiration date, manufacturer information, and applicable regulatory documentation.

The 2 mL vial volume is a packaging specification, not a recommended administration quantity. The liquid presentation does not independently establish authorization for a particular injection method.

Storage & Handling

Published Miracle H product documentation recommends storage in a cool, dry environment between 1°C and 30°C, protected from direct sunlight.

DEXLEVO-associated Miracle series materials also describe room-temperature storage at temperatures not exceeding 30°C.

• Reported Storage Temperature: Store between 1°C and 30°C according to published commercial specifications.
• Light Protection: Protect the product from direct sunlight.
• Original Packaging: Keep the vial in its original packaging until required for an authorized professional application.
• Container Integrity: Inspect the vial and closure for damage, leakage, or other evidence of compromised integrity.
• Handling After Opening: Follow the manufacturer's original instructions for use and disposal. Do not assume that unused contents may be stored for subsequent procedures.
• Product Traceability: Confirm the batch number, expiration date, product identity, and manufacturer information before professional handling.

Certain commercial distributors report a shelf life of 24 months. However, the applicable expiration period should be confirmed against the original manufacturer-issued labeling of the supplied product.

Published distributor storage recommendations should not replace manufacturer-validated requirements. The original product labeling takes precedence for storage temperature, shelf life, and handling after opening.

Safety & Regulatory Considerations

Miracle H is marketed for professional aesthetic applications involving a biodegradable PCL-based formulation. Its safety, intended administration route, and legally permitted uses must be assessed using the original product documentation and applicable national regulations.

Potential Adverse Reactions

Potential adverse reactions associated with injectable aesthetic biomaterials may include localized pain, swelling, redness, bruising, inflammation, infection, and hypersensitivity.

PCL-based injectable materials may also present risks of persistent nodules, granulomatous inflammation, and other delayed tissue reactions.

Serious injection-related complications can occur if a material enters or compromises a blood vessel. These may include vascular occlusion, tissue ischemia, necrosis, and other severe injuries.

The absence of conventional large polymer particles in a formulation does not guarantee freedom from these complications.

Polymer Biodegradation

Polycaprolactone is biodegradable, but biodegradability does not mean that an injected formulation is immediately removable or that adverse reactions are necessarily reversible.

PCL is chemically distinct from hyaluronic acid. The presence of HA in Miracle H does not establish that the entire formulation can be degraded using an HA-specific enzyme.

Material-specific management of complications requires appropriate medical evaluation.

Product-Specific Clinical Evidence

Clinical research involving other PCL dermal fillers provides scientific context for the potential of PCL-based biomaterials to stimulate collagen formation.

However, studies involving particulate PCL fillers or other DEXLEVO formulations cannot automatically establish the effectiveness or safety of Miracle H.

Claims of guaranteed collagen regeneration, immediate lifting, zero downtime, absence of adverse reactions, or effects lasting a full year require adequate clinical evidence specific to the finished Miracle H product.

Regulatory Authorization

Miracle H is commercially marketed as a PCL and HA skin booster. However, its current regulatory classification and authorized indications must be verified separately in each destination market.

Polycaprolactone has established uses in certain regulated medical devices, but approval of a raw material or another PCL-containing product does not establish regulatory approval for Miracle H.

US FDA approval for Miracle H has not been established. The authorization status of other PCL-based aesthetic products must not be attributed to Miracle H.

Professional buyers should verify the product's legal classification, registration status, original manufacturer labeling, permitted administration methods, and import eligibility before procurement.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish individual suitability, or authorize administration of an unapproved product.

Frequently Asked Questions